This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Methylselenocysteine
DrugBank Accession Number
DB12697
Background

Methylselenocysteine has been used in trials studying the prevention of Prostate Carcinoma and No Evidence of Disease.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 182.08
Monoisotopic: 182.979850365
Chemical Formula
C4H9NO2Se
Synonyms
  • SE-METHYL-SELENO-L-CYSTEINE

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ArticaineThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Cinchocaine.
CocaineThe risk or severity of methemoglobinemia can be increased when Methylselenocysteine is combined with Cocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
L-alpha-amino acids
Alternative Parents
Amino acids / Selenoethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Amine / Amino acid / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / L-alpha-amino acid / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxide
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
non-proteinogenic L-alpha-amino acid, Se-methylselenocysteine, L-selenocysteine derivative (CHEBI:27812)
Affected organisms
Not Available

Chemical Identifiers

UNII
TWK220499Z
CAS number
26046-90-2
InChI Key
XDSSPSLGNGIIHP-VKHMYHEASA-N
InChI
InChI=1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1
IUPAC Name
(2R)-2-amino-3-(methylselanyl)propanoic acid
SMILES
C[Se]C[C@H](N)C(O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0004113
KEGG Compound
C05689
PubChem Compound
147004
PubChem Substance
347828898
ChemSpider
129633
ChEBI
27812
ChEMBL
CHEMBL62382
Wikipedia
Methylselenocysteine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionHealthy, no Evidence of Disease1
1CompletedPreventionNo Evidence of Disease / Prostate Carcinoma1
1Not Yet RecruitingPreventionColorectal Adenomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility156.0 mg/mLALOGPS
logP-2.8ALOGPS
logP-3.5Chemaxon
logS-0.07ALOGPS
pKa (Strongest Acidic)1.46Chemaxon
pKa (Strongest Basic)8.4Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area63.32 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity38.2 m3·mol-1Chemaxon
Polarizability12.89 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-000i-2900000000-584579d62a5c494d1ad4
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-0i00-1960000000-c1d9d3d6c03ef447c682
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-MSGC-MSsplash10-000i-2900000000-584579d62a5c494d1ad4
GC-MS Spectrum - GC-MSGC-MSsplash10-0i00-1960000000-c1d9d3d6c03ef447c682
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001r-0900000000-87ae6338ccd9513f5db0
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001r-1900000000-204e0c71178a372a67d0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000f-9800000000-f08ef5fe840b11c1330b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00lu-5900000000-267cb39ae0470e212ce2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0079-9400000000-7ae0b50471ba90d5656c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-7580c3589d69535a4bb7

Drug created at October 20, 2016 23:40 / Updated at June 12, 2020 16:53